While tamoxifen, a SERM, which also binds to and inhibits ChEH, is prescribed to both pre- and post-menopausal women with ER + breast cancer, aromatase inhibitors are used to treat postmenopausal women with ER + breast cancer. This evidence concerns the gene CYP19A1 and breast carcinoma.